CD4+ and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Biomarkers: Role in Predicting the Stadium and Prognosis of Cervical Cancer
Abstract
Background: Tumor-infiltrating lymphocytes (TILs), mainly CD4+ and CD8 + T cells, have been extensively described in anti-tumor immunity, and knowledge of CD4+ and CD8+ T lymphocytes’ interplay in mediating the control of tumor growth exists. We use the role of TILs in predicting the prognosis of cervical cancer patients and develop the discovery of new immunotherapy strategies that specifically target TILs.
Methods: A systematic review of studies carried out a histopathological and immunohistochemical examination of TILs and an immunotherapy treatment.
Results: 10 articles were selected for a systematic review. Expression of TILs was associated with the progression of NIS to cervical cancer. CD4+ and CD8+ TILs can determine the stage and prognosis of cervical cancer. TILs immunotherapy is effective for all cervical cancer patients. Combination chemotherapy with anti-TILs immunotherapy and combination therapy for PD-1 and TILs was found to have a better potential for cervical cancer therapy.
Conclusions: TILs can be a prognostic biomarker and a marker to predict cervical cancer.
Keywords
References
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020 – 2030 [Internet]. Vol. 2, United Nations General Assembly. 2021. 1–3 p. Available from: https://www.who.int/publications/i/item/9789240014107.
Stelzle D. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Heal. 2021;9(2).
Hull R, Mbele M, Makhafola T, et al. Cervical cancer in low and middle.income countries (Review). Oncol Lett. 2020;20(3):2058–74.
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal. 2020;8(2):e191–203.
Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: an unmet grand challenge in global health Europe PMC Funders Group. Lancet. 2017;389(10071):847–60.
Songane M, Grossmann V. The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value. PLoS One. 2021;16(1 January):1–22.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Orbegoso C, Murali K, Banerjee S. The current status of immunotherapy for cervical cancer. Reports Pract Oncol Radiother. 2018;23(6):580–8.
Okunade KS. Human Papillomavirus and Cervical Cancer. J Obs Gynaecol. 2020;40(5):602–608.
LaCour DE, Trimble C. Human Papillomavirus in Infants: Transmission, Prevalence, and Persistence. J Pediatr Adolesc Gynecol. 2012;25(2):93–7.
van der Burg SH, Melief CJM. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol. 2011;23(2):252–7.
Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother. 2012;18(6):807–15.
Zhou C, Tuong ZK, Frazer IH. Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System. Front Oncol. 2019;9(August).
de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13.
Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020;10(January).
Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chinese J Cancer Res. 2020;32(6):720–8.
Jaisamrarn U, Castellsagué X, Garland SM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: Analysis of the control arm of the large, randomised PATRICIA study. PLoS One. 2013;8(11):1–15.
Gadducci A, Barsotti C, Cosio S, et al. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature. Gynecol Endocrinol. 2011;27(8):597–604.
Mwaka AD, Orach CG, Were EM, et al. Awareness of cervical cancer risk factors and symptoms: Cross-sectional community survey in post-conflict northern Uganda. Heal Expect. 2016;19(4):854–67.
Lukac A, Sulovic N, Smiljic S, et al. The Prevalence of the Most Important Risk Factors Associated with Cervical Cancer. Mater Socio Medica. 2018;30(2):131.
Burk RD, Chen Z, Saller C, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378–84.
Li X, Hu SY, He Y, et al. Systematic literature review of risk factors for cervical cancer in the Chinese population. Women’s Heal. 2018;14.
Hatano T, Sano D, Takahashi H, Oridate N. Pathogenic role of immune evasion and integration of human papillomavirus in oropharyngeal cancer. Microorganisms. 2021;9(5).
Senba M, Mori N. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol Rev. 2012;6(2):135–44.
Scott ME, Shvetsov YB, Thompson PJ, et al. Cervical Cytokines and Clearance of Incident Human Papillomavirus Infection: Hawaii HPV Cohort Study. Int J Cancer. 2013;133(5):1287–2296.
Peghini BC, Abdalla DR, Barcelos ACM, et al. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol. 2012;73(9):920–6.
Song D, Li H, Li H, Dai J. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer (Review). Oncol Lett. 2015;10(2):600–6.
Lee YS, Lee CW, Song MJ, et al. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia. Acta Obstet Gynecol Scand. 2011;90(12):1350–6.
Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(SUPPL. 1):S16.
De Freitas AC, De Oliveira THA, Barros MR, Venuti A. HrHPV E5 oncoprotein: Immune evasion and related immunotherapies. J Exp Clin Cancer Res. 2017;36(1):1–15.
Amador-Molina A, Hernández-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses. 2013;5(11):2624–42.
Hato T, Dagher PC. How the innate immune system senses trouble and causes trouble. Clin J Am Soc Nephrol. 2015;10(8):1459–69.
Frazer IH, Chandra J. Immunotherapy for HPV associated cancer. Papillomavirus Res. 2019;8(May):100176.
James CD, Das D, Bristol ML. Activating the DNA Damage Response and Suppressing Innate Immunity. Pathogens. 2020;467(9):2–15.
Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: An update. Int J Cancer. 2018;142(2):224–9.
Lechien JR, Descamps G, Seminerio I, et al. HPV involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas. Cancers (Basel). 2020;12(5):1–25.
Kazemi MH, Sadri M, Najafi A, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol. 2022;13(October):1–23.
Hendry S, Salgado R, Gevaert T, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors [Internet]. Vol. 24, Advances In Anatomic Pathology. 2017. 1 p. Available from: http://insights.ovid.com/crossref?an=00125480-900000000-99977.
Maskey N, Thapa N, Maharjan M, et al. Infiltrating CD4 and CD8 lymphocytes in hpv infected uterine cervical milieu. Cancer Manag Res. 2019;11:7647–55.
Cao M, Wang Y, Wang D, et al. Increased High-Risk Human Papillomavirus Viral Load Is Associated with Immunosuppressed Microenvironment and Predicts a Worse Long-Term Survival in Cervical Cancer Patients. Am J Clin Pathol. 2020;153(4):502–12.
Ohno A, Iwata T, Katoh Y, et al. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy. Gynecol Oncol. 2020;159(2):329–34.
Chen R, Gong Y, Zou D, et al. Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer. PeerJ. 2019;2019(10):1–23.
Wu Y, Ye S, Goswami S, et al. Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients. BMC Cancer. 2020;20(1):1–12.
Stevanovic S, Helman SR, Wunderlich JR, et al. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers. Clin Cancer Res. 2019;25(5):1486–93.
Komdeur FL, Prins TM, van de Wall S, et al. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology. 2017;6(9):1–14.
Rossetti RAM, Lorenzi NPC, Yokochi K, et al. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. PLoS One. 2018 Jul 5;13(7):e0199034. PLoS One. 2018;July 5:1–18.
Yin H, Guo W, Sun X, et al. TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer. J Immunol Res. 2020;2020.
Miyasaka Y, Yoshimoto Y, Murata K, et al. Treatment outcomes of patients with adenocarcinoma of the uterine cervix after definitive radiotherapy and the prognostic impact of tumor-infiltrating CD8+ lymphocytes in pre-treatment biopsy specimens: A multi-institutional retrospective study. J Radiat Res. 2020 Mar 23;61(2):275–84.
Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017 Apr 14;356(6334):200-5.
Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474(4):449–61.
DOI: 10.33371/ijoc.v16i4.906
Article Metrics
Abstract view : 136 timesPDF - 97 times
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Indonesian Journal of Cancer
Email this article 
